Covant Therapeutics
Matthew Cullen is a highly experienced professional in the field of medicinal chemistry and molecular pharmacology. Currently serving as Director at Covant Therapeutics since September 2022, Cullen previously held the role of Principal Investigator at Roivant Sciences from April 2021 to September 2022, following Roivant's acquisition of Silicon Therapeutics, where Cullen also served as Principal Investigator and led various chemistry projects. Prior experience includes a tenure as Senior Scientist I/Program Lead at Proteostasis Therapeutics, Inc., and a post-doctoral researcher position at the University of Illinois at Urbana-Champaign, specializing in synthetic organic chemistry. Cullen received a Ph.D. from Purdue University and a B.S. in Chemistry from UC Irvine.
This person is not in any teams
Covant Therapeutics
Operator of a covalent drug discovery company intended to create novel therapeutics by using covalency to imprint and regulate proteins. The company applies cutting-edge capabilities and expertise in chemistry, quantitative proteomics, translational sciences, and deep learning, enabling clients to translate discoveries into drugs.